Cancer by Momin, Behnoosh R. et al.
Liver Cancer Survival in the United States by Race and Stage 
(2001–2009): Findings From the CONCORD-2 Study
Behnoosh R. Momin, DrPH, MS, MPH1, Paulo S. Pinheiro, MD, PhD2, Helena Carreira, MSc3, 
Chunyu Li, MD, PhD, MS1, and Hannah K. Weir, PhD1
1Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, 
Georgia
2Epidemiology and Biostatistics, University of Nevada at Las Vegas, Las Vegas, Nevada
3Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London 
School of Hygiene and Tropical Medicine, London, United Kingdom
Abstract
BACKGROUND—Worldwide, liver cancer is a leading cause of death for both men and women. 
The number of Americans who are diagnosed with and die of liver cancer has been rising slowly 
each year. Using data from the CONCORD-2 study, this study examined population-based survival 
by state, race, and stage at diagnosis.
METHODS—Data from 37 statewide registries, which covered 81% of the US population, for 
patients diagnosed during 2001–2009 were analyzed. Survival up to 5 years was adjusted for 
background mortality (net survival) with state- and race-specific life tables, and it was age-
standardized with the International Cancer Survival Standard weights.
RESULTS—Liver cancer was diagnosed overall more often at the localized stage, with blacks 
being more often diagnosed at distant and regional stages than whites. 5-year net survival was 
12.2% in 2001–2003 and 14.8% in 2004–2009. Whites had higher survival than blacks in both 
calendar periods (11.7% vs 9.1% and 14.3% vs 11.4%, respectively). During 2004–2009, 5-year 
survival was 25.7% for localized-stage disease, 9.5% for regional-stage disease, and 3.5% for 
distant-stage disease.
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CONCLUSIONS—Some progress has occurred in survival for patients with liver cancer, but 5-
year survival remains low, even for those diagnosed at the localized stage. Efforts directed at 
controlling well-established risk factors such as hepatitis B may have the greatest impact on 
reducing the burden of liver cancer in the United States.
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INTRODUCTION
Worldwide, liver cancer is the fifth most common cancer among men, the ninth most 
common cancer among women, and the second most common cause of cancer death for men 
and women combined.1 Recent reports from North America, Europe, and Japan have shown 
that the incidence of hepatocellular carcinoma (HCC), the most common histological type, is 
increasing.2–5 The number of Americans who are diagnosed with and die of liver cancer 
each year has been rising slowly for several decades.6 In 2013, 21,143 men and 8330 women 
were diagnosed with liver cancer, and 16,300 men and 7732 women died of liver cancer.7 
According to the 2015 annual report to the nation, US death rates for most cancers declined 
or were stable from 2003 to 2012 among men and women of each racial and ethnic group; 
an exception was liver cancer, for which the incidence rates increased for most racial and 
ethnic groups.8 For men and women, US liver cancer incidence rates were highest among 
American Indians/Alaskan Natives, followed by Asian Pacific Islanders and Hispanics. Liver 
cancer incidence rates among US men were more than twice those among US women.8
Chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infection, and 
cirrhosis all contribute to the risk of HCC. HBV and HCV infections account for an 
estimated 78% of global HCC cases.9 In addition, excessive alcohol consumption, obesity, 
rare metabolic disorders, type 2 diabetes mellitus, and nonalcoholic fatty liver disease are 
other known risk factors for liver cancer.10 Most cases of HCC are preventable. Methods to 
reduce the risk of liver cancer include evidence-based strategies and interventions related to 
the risks associated with hepatitis. Vaccination against HBV infection for all infants at birth 
and for adults who may be at increased risk as well as testing for HCV and linking patients 
to follow-up care after testing leads to declines in the incidence of HCC.8
In contrast to many other cancers, the prognosis of patients with HCC is not highly 
correlated with the tumor stage. Cirrhosis underlies the neoplasm in most cases and has a 
major impact on the prognosis of patients with HCC.11 The CONCORD-2 study reported 
survival for patients with cancer diagnosed from 1995 through 2009 in 67 countries, and it 
enabled comparison of the survival of patients in the United States with the survival of 
patients in other countries.12 Liver cancer survival was low in all countries. The 5-year age-
standardized net survival for patients diagnosed with liver cancer in 2005–2009 was less 
than 20% everywhere in Europe, in the range 15% to 19% in North America, and as low as 
7% to 9% in Mongolia and Thailand. Between 1995–1999 and 2005–2009, 5-year age-
standardized net survival for patients with liver cancer increased in the United States from 
9% to 15%. This may be due to improved viral hepatitis services and medical management.
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In the current study, using the largest data set available (population-based registry data from 
37 states with 80.6% coverage of the US population), we expand the CONCORD-2 study by 
reporting liver cancer survival in the United States by race and stage at diagnosis. This 
information is critical for prioritizing, planning, and implementing cancer control 
interventions.
MATERIALS AND METHODS
Data Source and Variables
Thirty-seven state cancer registries that were affiliated with the National Program of Cancer 
Registries or the Surveillance, Epidemiology, and End Results Program and that participated 
in the CONCORD-2 study,12 covering 81% of the US population, agreed to the inclusion of 
their data in these analyses. We analyzed individual tumor records for 126,261 adults (aged 
15–99 years) who were diagnosed with cancer of the liver or intrahepatic bile ducts 
(International Classification of Diseases for Oncology, 3rd edition, codes C22.0-C22.1)13 
during 2001–2009 and were followed up through December 31, 2009. We included the first 
primary, invasive cancer of the liver, regardless of whether an individual had a previous 
cancer. If an individual was diagnosed with 2 or more cancers of the liver between 2001 and 
2009, only the first was considered in the survival analysis.
We grouped patients by the year of diagnosis into 2 calendar periods (2001–2003 and 2004–
2009) to reflect changes in the methods used by US registries to collect Surveillance, 
Epidemiology, and End Results Summary Stage 2000 (SS2000) data at diagnosis.14 During 
2001–2003, most registries coded SS2000 directly from the medical records. During 2004–
2009, all registries derived SS2000 with the Collaborative Staging System.15
Survival Analyses
We analyzed survival by state, race (all races, black, and white), SS2000 (local, regional, 
distant, and unknown), and calendar period of diagnosis. Using the Pohar Perme estimator16 
we estimated net survival up to 5 years after diagnosis, with 95% confidence intervals. Net 
survival can be interpreted as the probability of survival up to a given time since diagnosis, 
after one has controlled for other causes of death (background mortality). To control for the 
wide differences in background mortality between participating states, we constructed life 
tables17 of all-cause mortality in the general population of each state from the number of 
deaths and the population by single year of age, sex, calendar year, and, whenever possible, 
race (black or white), with a flexible Poisson model.18
We estimated net survival with the cohort approach for patients diagnosed in 2001–2003 
because all patients had been followed up for at least 5 years by December 31, 2009. We 
used the complete approach to estimate net survival for patients diagnosed from 2004–2009 
because 5 years of follow-up data were not available for all patients. Net survival was 
estimated for 5 age groups (15–44, 45–54, 55–64, 65–74, and 75–99 years). We obtained 
age-standardized survival estimates with the International Cancer Survival Standard 
weights.19 If 2 or more of the 5 age-specific estimates could not be obtained, we present 
only the pooled, unstandardized survival estimates for all ages combined. Unstandardized 
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estimates are italicized in the tables. Trends, geographic variations, and differences in age-
standardized net survival by race are presented graphically in bar charts and funnel plots.20 
Funnel plots of net survival for 2001–2003 and 2004–2009 provide insight into the 
variability of cancer survival in the United States by race and state, and show how much a 
particular survival estimate deviates from the pooled estimate of US registries (horizontal 
line) given the precision of each estimate. More details on data and methods are provided in 
the accompanying article.21
RESULTS
Liver cancer case distribution by race and stage at diagnosis by calendar period of diagnosis 
is reported in Table 1. In 2004–2009, liver cancer was mostly diagnosed at the localized 
stage (overall 41%), which was followed by the regional (24%) and distant stages (18%). 
The stage at diagnosis varied slightly by race, with blacks being more often diagnosed at 
distant and regional stages (20% and 26%, respectively, vs 17% and 24% for whites). 
However, state-specific analyses showed that the proportion of patients with an unknown 
stage at diagnosis ranged from 8% to 30%, and this makes accurate comparisons by race at 
the national level difficult (Supporting Table 1). Between the 2 calendar periods, there is an 
indication of a shift toward an earlier diagnosis of liver cancer, with an increase of 8% with 
localized-stage disease, an increase of 2% with regional-stage disease, and an increase of 
less than 1% with for distant-stage disease. In addition, there was a substantial decline in the 
proportion of cases recorded with an unknown stage at diagnosis (from 26% to 17%).
Although 5-year age-standardized net survival was low in the US (12% in 2001–2003 and 
15% in 2004–2009), an improvement between the 2 calendar periods was observed (Fig. 1). 
Age-standardized estimates were available for 35 states; net survival increased between 
2001–2003 and 2004–2009 in 30 states, whereas only 5 states showed a decrease. There was 
considerable variation by state in 2004–2009 in 5-year survival, which ranged from 8.1% in 
Wyoming to 20.9% in Florida (Supporting Table 2).
The 1-, 3-, and 5-year age-standardized net survival estimates for 2004–2009 were 38%, 
21%, and 15%, respectively (Table 2). At each of these 3 time points, blacks showed lower 
age-standardized net survival than whites for all states combined. The difference was most 
pronounced in the first year after diagnosis, and this suggests that blacks have lower survival 
in the short term in addition to lower survival 5 years after the diagnosis. Only 4 states 
(Alabama, Michigan, North Carolina and Texas) in 5-year age-standardized net survival had 
a survival disadvantage for blacks versus whites. There was, however, a 5-year survival 
improvement for both races from 2001–2003 to 2004–2009: an absolute increase of 2.6% for 
whites and a 2.3% increase for blacks. The 5-year age-standardized net survival was 14.3% 
for whites and 11.4% for blacks. Overall 5-year survival for all races combined was 14.8%, 
which was higher than survival for both blacks and whites.
The 5-year age-standardized net survival estimates by stage (Table 3) for 2004–2009 were 
uniformly low at 26%, 10%, and 4% for localized, regional, and distant stages, respectively. 
For the localized stage, increases in survival were observed between 2001–2003 and 2004–
2009 with a 2.8% increase for all races, a 2.4% increase for whites, and a 5.0% increase for 
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blacks. For regional and distant stages, smaller increases were observed, except for blacks 
diagnosed with regional-stage disease, for whom there was a decline in survival of 1%. 
Although 5-year net survival was low in all states, there was considerable variation by stage 
and state (Supporting Table 3).
Figure 2 shows funnel plots of net survival for 2001–2003 and 2004–2009 to provide further 
insight into the variability of liver survival in the United States by race and state. Although 
survival for patients with liver cancer was generally low in all states in both calendar 
periods, survival for black patients was lower than survival for white patients, and in most 
states, it was lower than the pooled US value.
DISCUSSION
Using recent population-based data, this study reports the most comprehensive comparison 
of trends in the United States for 5-year survival for patients with liver cancer. The 5-year 
age-standardized net survival for patients with liver cancer reported in this analysis was low 
(15%) for the most recent period, but it was slightly higher than in 2001–2003 (12%). This 
slight increase may be partially explained by the increased proportion of patients diagnosed 
at the localized stage, who have shown improved survival in the most recent years. Five-year 
survival in the United States is slightly lower but is still closely aligned with the 5-year 
survival estimates of Canada (17.7% [16.8%–18.7%], 2005–2009) and is slightly higher than 
survival in the United Kingdom (9.3% [8.7–9.9%], 2005–2009).12 This study noted some 
variations in survival by state and race. Whites had higher survival than blacks in both 
calendar periods. In addition, five-year net survival was higher in white women than white 
men, and higher in black women than black men (data not shown). The survival advantage 
for women contrasts with the findings reported for Europe in the late 1990s: Micheli et al22 
reported an advantage for women for 11 of 26 cancer sites; this advantage was not reported 
for liver cancer. This difference may reflect a difference in US and European populations. 
An early diagnosis of liver cancer is challenging because many of the symptoms associated 
with this disease do not present until later stages. In addition, because of the location of the 
liver beneath the rib cage, liver tumors are difficult to detect.
This study suggests that there has been some improvement in liver cancer survival. 
Advances in treatment strategies have likely contributed to this improvement. Surgical 
resection, liver transplantation, and ablation are associated with best long-term survival. 
Surgical resection is usually performed in patients with localized HCC and sufficient 
preserved liver function. Liver transplantation is the best option for patients with 
decompensated cirrhosis and a solitary lesion (<5 cm) or early multifocal disease (≤3 
lesions, ≤3 cm in diameter).23 When liver resection or transplantation is feasible, ablation 
may be used, particularly for patients with early-stage HCC that is centrally located in the 
liver. Disparities in access to and receipt of appropriate surgical care may play an essential 
role in the racial differences that we observed in liver cancer survival. Studies have shown 
that African Americans and Asians with localized HCC are significantly less likely to 
receive a transplant than their white counterparts.24 In addition, African American patients 
have been found to be younger and to have a more advanced stage of disease than white 
patients, and they are also more likely to die while waiting for a transplant.25 However, 
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survival disparities by race may not be explained by differences in care only. Artinyan et al26 
reported that racial differences in survival remained significant among patients who 
underwent liver transplantation.
Clinical Implications
To improve the survival of patients with liver cancer, adherence to evidence-based treatment 
protocols among all population groups, and other factors, including biologic factors, 
responses to therapy, patient comorbidities, posttreatment follow-up and care, and tumor 
recurrence, all need to be considered. Increased recruitment of non-white populations to 
liver cancer clinical trials may help to alleviate racial differences in survival and improve the 
understanding of race-based differences in cancer biology.27 HBV or HCV can cause 
persistent active hepatitis and hepatic fibrosis, which lead to the development of HCC and 
also have a major impact on the prognosis of patients with HCC by affecting the rate of 
recurrence after surgery.28–30 Interferon therapy has shown to be beneficial for patients with 
hepatitis virus–associated HCC and can improve their outcome after curative resection.31
Cancer Control Implications
Because most liver cancers are preventable,8 cancer control efforts and resources that 
support preventing infection and promoting viral hepatitis services should be 
prioritized.8,32,33 Approximately 22% of HCC cases among those 65 years old or older in 
the United States can be attributed to HCV,10 and an estimated 1.6 million persons will be 
eligible for HCV treatment by 2020.34 Antiviral therapies for HBV and HCV can help to 
prevent liver cancer, and they also result in decreased neuroinflammation in the liver and 
over time cause a reversal of fibrosis, which also leads to a decreased HCC risk.35 In 2012, 
the CDC recommended 1-time HCV testing for persons born from 1945 to 1965 (47–67 
years old in 2012).36 In the following year, the US Preventive Services Task Force issued 
similar recommendations.37 According to the National Academies of Science, Engineering, 
and Medicine,38 limited public and provider awareness and limited public resource 
allocation are the primary underlying causes of high rates of chronic HBV and HCV 
infections in the United States.38 In the United States, Asians have the highest incidence of 
HBV infection.39 However, for other populations (non-Asians), the incidence of HBV 
infection is not as much a concern as the incidence of HCV infection, which assumes a 
bigger role in the etiology of liver cancer.40 For the latter group, the patterns among 
immigrants are consistent and sex-specific: males, when coming to the United States, have 
higher incidence and mortality rates, but females have stabilized or slightly decreased rates. 
This has been shown for different populations (Hispanics and non-Hispanic blacks).41–43 
The CDC’s National Comprehensive Cancer Control Program is currently working on the 
development and implementation of an action plan that would facilitate greater 
implementation and uptake of strategies within selected pilot programs among population 
groups that have a high liver cancer burden.44 The action plan will contain interventions 
specific to increasing support for vaccine-based strategies to eliminate HBV transmission 
and for the development of prevention and health services that include screening for HBV 
and HCV infections, linked to appropriate medical management and care (in alignment with 
recommendations), community education about HBV and HCV, and the improvement of 
viral hepatitis surveillance. Improved surveillance for HBV and for patients with HCV-
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related cirrhosis has the potential to result in the detection of more cancers at a localized 
stage, when surgery may be possible and more beneficial.45
Strengths and Limitations
This analysis has several strengths, including the inclusion of a very large number of US 
states, which makes it the most geographically comprehensive survival study to our 
knowledge. Also, the sophisticated and complex methodology takes into account competing 
risks of death, which are higher for elderly cancer patients than younger cancer patients. 
Finally, more than 70% of all the cases included in this analysis were morphologically 
verified, and this contributed to the high quality of the data used.
A limitation of our analysis is that some stage and race categories had missing data or small 
numbers. The small black population in some states precluded the construction of life tables 
for the black populations in these states; therefore, the state-specific life tables for all races 
combined were used instead. In addition, data on populations with a higher burden of liver 
cancer, including Asians/Pacific Islanders and Hispanics, were not collected or analyzed in 
this study.
In conclusion, the incidence of cancer in the United States is expected to increase greatly 
because of demographic changes such as an aging population and a larger proportion of 
individuals from non-White racial/ethnic groups; it is estimated that liver cancer will have 
the second highest increase (59%) between 2010 and 2030 among all cancer sites.46 This 
analysis suggests some progress in 5-year survival for liver cancer in the United States; 
however, there is still much more work that needs to be done to reduce the burden of this 
cancer. Improvements in the surveillance, prevention, and detection of HBV and HCV 
infections may have the greatest potential for earlier detection and thus increased survival.
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Figure 1. 
Liver cancer: 5-year age-standardized net survival for males and females (15–99 years old) 
diagnosed 2001–2003 and 2004–2009 and absolute changes (%). The states are grouped by 
US Census region. Data from 37 statewide cancer registries (covering 80.6% of the 
population) are ranked within US Census regions by decreasing survival estimate for 2004–
2009. Dark colors denote states affiliated with the National Program of Cancer Registries; 
pale colors denote states affiliated with the Surveillance, Epidemiology, and End Results 
Program; and an asterisk denotes states affiliated with both federal surveillance programs. † 
Indicate changes were not plotted if a survival estimate was not available for 1 calendar 
period or if 1 or more estimates were not age-standardized.
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Figure 2. 
Liver cancer: 5-year age-standardized net survival for males and females (15–99 years old) 
by state, race, and calendar period of diagnosis. The pooled (US) survival estimate for each 
calendar period is shown by the horizontal (solid) line with corresponding 95.0% and 99.8% 
control limits (dotted lines).
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